These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19296131)

  • 1. Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).
    van Kuilenburg AB; Meijer J; Mul AN; Hennekam RC; Hoovers JM; de Die-Smulders CE; Weber P; Mori AC; Bierau J; Fowler B; Macke K; Sass JO; Meinsma R; Hennermann JB; Miny P; Zoetekouw L; Vijzelaar R; Nicolai J; Ylstra B; Rubio-Gozalbo ME
    Hum Genet; 2009 Jun; 125(5-6):581-90. PubMed ID: 19296131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c.505_513del of DPYD.
    van Kuilenburg AB; Meijer J; Gökcay G; Baykal T; Rubio-Gozalbo ME; Mul AN; de Die-Smulders CE; Weber P; Mori AC; Bierau J; Fowler B; Macke K; Sass JO; Meinsma R; Hennermann JB; Miny P; Zoetekouw L; Roelofsen J; Vijzelaar R; Nicolai J; Hennekam RC
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):509-14. PubMed ID: 20544545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
    Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
    BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12.
    van Kuilenburg ABP; Tarailo-Graovac M; Meijer J; Drogemoller B; Vockley J; Maurer D; Dobritzsch D; Ross CJ; Wasserman W; Meinsma R; Zoetekouw L; van Karnebeek CDM
    Hum Mutat; 2018 Jul; 39(7):947-953. PubMed ID: 29691939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.
    van Kuilenburg AB; Meijer J; Mul AN; Meinsma R; Schmid V; Dobritzsch D; Hennekam RC; Mannens MM; Kiechle M; Etienne-Grimaldi MC; Klümpen HJ; Maring JG; Derleyn VA; Maartense E; Milano G; Vijzelaar R; Gross E
    Hum Genet; 2010 Nov; 128(5):529-38. PubMed ID: 20803296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.
    Saarenheimo J; Wahid N; Eigeliene N; Ravi R; Salomons GS; Ojeda MF; Vijzelaar R; Jekunen A; van Kuilenburg ABP
    Cancer Chemother Pharmacol; 2021 May; 87(5):657-663. PubMed ID: 33544210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
    Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
    Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
    Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
    Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD).
    Hormozian F; Schmitt JG; Sagulenko E; Schwab M; Savelyeva L
    Cancer Lett; 2007 Feb; 246(1-2):82-91. PubMed ID: 16556484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
    Fischer J; Schwab M; Eichelbaum M; Zanger UM
    Genet Test; 2003; 7(2):97-105. PubMed ID: 12885330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder.
    Carter MT; Nikkel SM; Fernandez BA; Marshall CR; Noor A; Lionel AC; Prasad A; Pinto D; Joseph-George AM; Noakes C; Fairbrother-Davies C; Roberts W; Vincent J; Weksberg R; Scherer SW
    Clin Genet; 2011 Nov; 80(5):435-43. PubMed ID: 21114665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
    Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
    Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
    Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
    Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
    Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
    Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
    Gross E; Seck K; Neubauer S; Mayr J; Hellebrand H; Ratanaphan A; Lutz V; Stockinger H; Kiechle M
    Int J Oncol; 2003 Feb; 22(2):325-32. PubMed ID: 12527930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
    De Luca O; Salerno G; De Bernardini D; Torre MS; Simmaco M; Lionetto L; Gentile G; Borro M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.
    Ben Fredj R; Gross E; Chouchen L; B'Chir F; Ben Ahmed S; Neubauer S; Kiechle M; Saguem S
    C R Biol; 2007 Oct; 330(10):764-9. PubMed ID: 17905396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.